Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

We conducted a dose escalation Phase 1 study of autologous PBMCs loaded by microfluidic squeezing (Cell Squeeze(®) technology) with HPV16 E6 and E7 antigens (SQZ-PBMC-HPV), in HLA-A*02+ patients with advanced/metastatic HPV16+ cancers. Preclinical studies in murine models had shown such cells result...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimeno, Antonio, Baranda, Joaquina, Iams, Wade T., Park, Jong Chul, Mita, Monica, Gordon, Michael S., Taylor, Matthew, Dhani, Neesha, Leal, Alexis D., Neupane, Prakash, Eng, Cathy, Yeku, Oladapo, Mita, Alain, Moser, Justin C., Butler, Marcus, Loughhead, Scott M., Jennings, Julia, Miselis, Nathan R., Ji, Rui-Ru, Nair, Nitya, Kornacker, Martin, Zwirtes, Ricardo F., Bernstein, Howard, Sharei, Armon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140074/
https://www.ncbi.nlm.nih.gov/pubmed/36867316
http://dx.doi.org/10.1007/s10637-023-01342-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140074/
https://www.ncbi.nlm.nih.gov/pubmed/36867316
http://dx.doi.org/10.1007/s10637-023-01342-x

Ejemplares similares